GHTC issued a statement at the 144th session of the World Health Organization (WHO) Executive Board urging Member States to realign National TB Strategic Plans, including on research and development, to fulfill the commitments of the High-Level Meeting (HLM) on Tuberculosis. The statement, which was issued in partnership with the Global Health Council, American Academy of Pediatrics, and ACTION, welcomed the HLM's attention to the neglected needs of children, which affects approximately one million children annually.
GHTC issued a statement at the 144th session of the World Health Organization (WHO) Executive Board supporting the ongoing efforts of WHO to increase equitable access to medicines, vaccines, and other health products. The statement, which was issued in partnership with the Global Health Council, the American Academy of Pediatrics, and NCD Child, encourages WHO to support a comprehensive approach to improving access that considers affordability, acceptability, availability, and quality.
GHTC submitted comments to a US Department of Health and Human Services request for information (RFI)on the next National Action Plan for Combatting Antibiotic Resistant Bacteria (CARB) 2020-2025. GHTC’s submission encouraged the prioritization of R&D to combat antimicrobial resistance globally.
GHTC applauds yesterday's Senate passage of the Global Health Innovation Act, a bipartisan bill to support efforts by the US Agency for International Development to develop affordable, appropriate technologies to advance the health of people in the world’s poorest places. The bill, which has already passed the House of Representatives, now heads to the President’s desk where he is expected to sign it into law.
GHTC sent a letter to Secretary of Health and Human Services Alex Azar in support of the National Biodefense Strategy released by the Administration in September. The letter commends the goals in the strategy aimed at accelerating basic and applied R&D of new antimicrobials, novel therapeutics, vaccines, and diagnostic tests; promoting increased global capacities for R&D, and integrating R&D into federal planning before and during a potential bio-incident.
GHTC applauds yesterday's Senate passage of the Global Health Innovation Act, a bipartisan bill to support efforts by the US Agency for International Development to develop affordable, appropriate technologies to advance the health of people in the world’s poorest places. The bill, which has already passed the House of Representatives, now heads to the President’s desk where he is expected to sign it into law.
GHTC yesterday honored Senator Roy Blunt (R-MO) and Congresswoman Rosa DeLauro (D-CT) at its second annual Innovating for Impact Awards, which celebrates US policymakers and partnerships driving progress in global health innovation. GHTC also recognized the partnership that developed and introduced improved child-friendly tuberculosis (TB) medicines, making these transformative treatments available to children in need worldwide.
GHTC has opened nominations for its 2018 Innovating for Impact Awards. Now in its second year, this initiative celebrates the partnerships and policymakers driving global health innovation. The nomination deadline is August 17, 2018.
GHTC welcomes the publication today by the World Health Organization (WHO) of its first Essential Diagnostics List, a critical new tool to help guide governments on the vital diagnostic tests that should be made available through health care systems.
The Trump Administration’s proposal to slash funding to fight global health threats like malaria, Ebola, and HIV/AIDS could cost states thousands of jobs and millions of dollars in economic investment and put the health of residents at risk, according to a new state-by-state analysis released today on Capitol Hill by the Global Health Technologies Coalition.
In this regular feature on Breakthroughs, we highlight some of the most interesting reads in global health research from the past week.
In this regular feature on Breakthroughs, we highlight some of the most interesting reads in global health research from the past week.
In this regular feature on Breakthroughs, we highlight some of the most interesting reads in global health research from the past week.
On February 15, President Trump signed into law a bipartisan spending bill—averting another partial government shutdown and ensuring full-year funding for the government for the remainder of fiscal year 2019. The months-long saga ended with some great news for global health and research and development.
In this regular feature on Breakthroughs, we highlight some of the most interesting reads in global health research from the past week.
A joint statement developed by GHTC and delivered at the 71st World Health Assembly (WHA) was cited in an article in Homeland Preparedness News.
GHTC analysis regarding the implication's of the President's budget proposal on funding for the US Centers for Disease Control and Prevention was cited in an article in Science.
GHTC's advocacy for an Essential Diagnostic List was cited in an article in Plus, an online magazine of HIV-related news.
GHTC Director Jamie Bay Nishi was quoted in a Devex article previewing the debates taking place at the 71st World Health Assembly.
Contagion quoted GHTC Director Jamie Bay Nishi in article covering the launch of the first-ever Essential Diagnostics List by the World Health Organization.
GHTC issued a statement at the 144th session of the World Health Organization (WHO) Executive Board urging Member States to realign National TB Strategic Plans, including on research and development, to fulfill the commitments of the High-Level Meeting (HLM) on Tuberculosis. The statement, which was issued in partnership with the Global Health Council, American Academy of Pediatrics, and ACTION, welcomed the HLM's attention to the neglected needs of children, which affects approximately one million children annually.
GHTC issued a statement at the 144th session of the World Health Organization (WHO) Executive Board supporting the ongoing efforts of WHO to increase equitable access to medicines, vaccines, and other health products. The statement, which was issued in partnership with the Global Health Council, the American Academy of Pediatrics, and NCD Child, encourages WHO to support a comprehensive approach to improving access that considers affordability, acceptability, availability, and quality.
GHTC submitted comments to a US Department of Health and Human Services request for information (RFI)on the next National Action Plan for Combatting Antibiotic Resistant Bacteria (CARB) 2020-2025. GHTC’s submission encouraged the prioritization of R&D to combat antimicrobial resistance globally.
GHTC sent a letter to Secretary of Health and Human Services Alex Azar in support of the National Biodefense Strategy released by the Administration in September. The letter commends the goals in the strategy aimed at accelerating basic and applied R&D of new antimicrobials, novel therapeutics, vaccines, and diagnostic tests; promoting increased global capacities for R&D, and integrating R&D into federal planning before and during a potential bio-incident.
GHTC joined other global health organizations in sending a letter to Secretary of Health and Human Services Alex Azar welcoming the Administration's recommitment to the Global Health Security Agenda (GHSA) and urging the Administration to provide robust funding for global health security activities in the fiscal year (FY) 2020 budget and release the Global Health Security Strategy required by Congress in the FY18 appropriations omnibus.
